Exosome data presented at ISCT conference

RNS Number : 1028N

ReNeuron Group plc

04 May 2018

 

 

AIM: RENE

4 May 2018

ReNeuron Group plc

("ReNeuron" or the "Company")

Exosome data presented at ISCT conference

Positive pre-clinical data in cancer with ReNeuron's ExoPr0 exosome therapy candidate accepted for podium presentation at the 2018 International Society of Cell Therapy (ISCT) annual meeting

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new and positive pre-clinical data relating to its ExoPr0 stem cell-derived exosome therapy candidate will be presented today at ISCT 2018, a leading scientific conference taking place this week in Montreal, Canada.

Exosomes are nanoparticles secreted from many different types of cells, including the Company's proprietary CTX stem cell line. They play a key role in cell-to-cell signalling, and early research with ExoPr0 has demonstrated their potential as both a novel therapeutic candidate and as a drug delivery vehicle.

Dr Randolph Corteling, Head of Research at ReNeuron, will present data demonstrating for the first time that the ExoPr0 candidate induces apoptosis (cell death) and/or senescence (arresting of cell growth) in a number of cancer cell lines.  The podium presentation will also show for the first time that ExoPr0 significantly reduces tumour volume in a variety of in vivo xenograft models of cancer.  These results, albeit early-stage, are particularly encouraging as they demonstrate the potential of ExoPr0 as a monotherapy with a comparable efficacy profile to the standard of care in a relevant cancer model.  Further, when combined with the current standard of care therapy, ExoPr0 induces an additive reduction of tumour volume, indicating distinct mechanisms by which ExoPr0 exerts its therapeutic effect as well as its potential utility as a combination therapy.

ReNeuron continues to build the pre-clinical data package for its ExoPr0 exosome therapy candidate and has recently commenced discussions with regulatory authorities regarding the potential regulatory pathway to the clinic for ExoPr0. Subject to continued success with ongoing pre-clinical development work, the Company hopes to be able to commence clinical development with ExoPr0 during 2019.

Further information about this conference may be found at www.isct2018.com.

Commenting on the data, Dr Randolph Corteling, Head of Research at ReNeuron, said:

"The data being presented at the ISCT 2018 conference represent a further advance in the development of our ExoPr0 exosome therapeutic candidate.  We draw considerable encouragement from these new pre-clinical results and look forward to presenting further progress with the development of ExoPr0 as a potential new and highly novel cancer therapy in the months ahead."

Capital markets event:

As previously announced, ReNeuron will be hosting a capital markets event on the Company's exosome nanomedicine platform on Thursday 17 May 2018. The event, for analysts and institutional investors, will take place at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For further details please contact Buchanan on 020 7466 5000.

ENDS

Enquiries:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Stephanie Watson
Stifel Nicolaus Europe Limited Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)	[phone]
N+1 Singer Advisory LLP Mark Taylor (Joint Broker)	[phone]

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. 

 

END

 

 

MSCEAESDELAPEAF